ACE-inhibitors but Not Endothelin Receptor Blockers Prevent Podocyte Loss in Early Diabetic Nephropathy

Diabetologia - Germany
doi 10.1007/s00125-003-1106-8
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Prevention of Dementia by ACE Inhibitors and Angiotensin Receptor Blockers - Potential but Not Proven

International Journal of Clinical Practice
Medicine
2010English

Does the Use of ACE Inhibitors or Angiotensin Receptor Blockers Affect Bone Loss in Older Men?

Osteoporosis International
MedicineEndocrinologyMetabolismDiabetes
2011English

Loss of PTEN Promotes Podocyte Cytoskeletal Rearrangement, Aggravating Diabetic Nephropathy

Journal of Pathology
Forensic MedicinePathology
2015English

Podocyte Autophagy: A Potential Therapeutic Target to Prevent the Progression of Diabetic Nephropathy

Journal of Diabetes Research
EndocrinologyMetabolismDiabetes
2017English

ACE Inhibition and Diabetic Nephropathy

BMJ
1991English

Glomerular Mesangial Cell and Podocyte Injuries in Diabetic Nephropathy

Nephrology
MedicineNephrology
2018English

Angiotensin-Converting Enzyme Inhibitors (ACE-Is) Versus Angiotensin- Receptor Blockers (ARBs): Any Superiority?

Journal of Hypertension- Open Access
2012English

ACE Inhibition and Diabetic Nephropathy: Author's Reply

BMJ
1991English

Interaction of Spironolactone With ACE Inhibitors or Angiotensin Receptor Blockers: Analysis of 44 Cases

BMJ
2003English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy